Rahul Singhvi, Resilience CEO

Bridge­Bio part­ners with bio­man­u­fac­tur­er Re­silience to pro­duce ear­ly-stage AAV gene ther­a­pies

Bridge­Bio has tapped bio­man­u­fac­tur­ing com­pa­ny Na­tion­al Re­silience to pro­duce two of its ear­ly-phase ade­no-as­so­ci­at­ed virus (AAV) gene ther­a­pies in a part­ner­ship de­signed to run be­yond …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA